HERE And Sigfox Join Forces to Create Global IoT Location Service for Logisitics and Supply Chain Sectors
30.5.2018 15:11:00 EEST | Business Wire | Press release
HERE Technologies and Sigfox today announced a partnership to develop and deploy a global location service that will open new opportunities for IoT applications, particularly in supply chain and logistics.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180530005612/en/
By integrating global coverage of wifi hotspots from HERE with the Sigfox worldwide network and geolocation engine, industry and consumers will be able to locate their assets everywhere, both indoors (including inside factories warehouses and other buildings) and outdoors, without any additional infrastructure, regardless of the size and quantity of assets.
The use of IoT asset tracking solutions in the global supply chain and logistics sector could create $1.9 trillion of economic value, according to Cisco and DHL, the world’s largest logistics provider. Current Real Time Location Services (RTLS) solutions are not always viable due to the high cost sensitivity and the short battery life constraints. This partnership also expands asset tracking opportunities for companies that could not previously afford geolocation services. The unique combination of both HERE and Sigfox technologies and their worldwide footprint enables clients to not only locate their assets, but to collect useful data that will help them to optimize their flows, ensure better transport conditions and increase service reliability. Use cases currently in live phase include air transport, luggage/trolley management, location of stolen/missing cars cars, industrial asset management and location of shipping containers.
«Our partnership with Sigfox reinforces HERE as a major player in IoT» said Christophe Hamaide, Senior Account Executive at HERE. « The HERE Location Suite references billions of Wi-Fi hotspots, and through this joint initiative, we will be able to pinpoint the location of millions of connected objects all around the world in the coming years. »
“This partnership is another major step to accomplish Sigfox’s ambitious vision to become the most competitive provider of industrial data in IoT” said Laetitia Jay, Chief Marketing Officer at Sigfox. “Locating assets while guaranteeing the lowest total cost of ownership of the solution is a key driver for logistics and supply chain industry to benefit from massive IoT business impact.”
For more information on Sigfox, visit Twitter or LinkedIn.
For more information on HERE Technologies, visit www.here.com
* http://www.businessinsider.fr/us/asset-tracking-in-the-supply-chain-and-logistics-2016-9
About Sigfox
Sigfox is the world’s leading IoT service
provider thanks to its global network that connects billions of devices
to the Internet while consuming as little energy as possible, as simply
as possible. Sigfox’s unique approach to device-to-cloud communications
addresses the three greatest barriers to global IoT adoption: cost,
energy consumption, and global scalability.
Today, the network is present in 45 countries and on track to cover 60 by 2018. With millions of objects connected and a rapidly growing partner ecosystem, Sigfox empowers companies to move their business model towards more digital services. Founded in 2010 by Ludovic Le Moan and Christophe Fourtet, the company is headquartered in Labège near Toulouse, France’s “IoT Valley”. Sigfox also has offices in Paris, Madrid, Munich, Boston, San Francisco, Dubai, Singapore, Sao Paulo and Tokyo.
About HERE Technologies
HERE, the Open Location Platform
company, enables people, businesses and cities to harness the power of
location. By making sense of the world through the lens of location we
empower our customers to achieve better outcomes – from helping a city
manage its infrastructure or a business optimize its assets to guiding
drivers to their destination safely. To learn more about HERE, including
our new generation of cloud-based location platform services, visit http://360.here.com
and www.here.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180530005612/en/
Contact information
Media Contacts:
Sigfox – Elan Edelman
sigfoxfrance@elanedelman.com
Pauline
Persyn - 06 20 43 84 67
Luisa Vittadini - 01 86 21 50 51
or
HERE
- Agence AxiCom
Constance Falourd – 01 56 02 68 25
constance.falourd@axicom.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom